Matt Gline (L) and Vivek Ramaswamy
Vivek Ramaswamy and Matt Gline swoop into Nasdaq on the wings of Jim Momtazee's SPAC with a $7B-plus Roivant debut ready to do some deals
Seven years after founding Roivant Sciences as an upstart contender in the world of biotech creation, Vivek Ramaswamy and his recently anointed CEO Matt …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
